CONFERENCE POSTER
Study of the Initial Response to Lopinavir/ritonavir in HIV Treatment
Experienced Patients: The ATU Pre-Registration Cohort in France.
P. NgoVan, et al.
PDF Poster

CONFERENCE POSTER
Lopinavir/ritonavir Pre-Registrational Usage in France (ATU): A 2000 to 2001
Insight into theTherapeutic Trends and Outcome in HIV Treatment Patients.
Cohen Codar, et al.
PDF Poster

CONFERENCE POSTER
Efficacy of Lopinavir/ritonavir in Multiple PI-Experienced Patients According
to Mutational Patterns: Data from the French ATU Program.
V. Calvez, et al.
PDF Poster

CONFERENCE POSTER
Collection of Drug Adverse Events in Pre-Registration Access Programs:
What Relevance Compared to Controlled Studies? Analysis of the
French ATU Cohort for Kaletra.
E.Boer et al.
PDF Poster

CONFERENCE POSTER
Efficacy and Safety Results from the LPV/r Early Access Program in
Germany.
JK Rockstroh, et al.
PDF Poster

CONFERENCE POSTER
Initial Efficacy and Safety Results from the Lopinavir/ritonavir (LPV/r,
 Kaletra) Early Access Program in Italy.
A Germinario, et al
PDF Poster

CONFERENCE POSTER
Efficacy amd Safety Results of Lopinavir-Based HAART Treatment
in Expanded Access Program in Spain Through W24.
B. Clotet, et al.
PDF Poster

CONFERENCE POSTER
Kaletra (Lopinavir/ritonavir) Therapy in Single Protease Inhibitor Patients:
144-Week Follow-up.
C. Hicks, et al.
PDF Poster

CONFERENCE POSTER
Kaletra (lopinavir/ritonavir) in Antiretroviral-Naive HIV+ Patients: 3-Year Follow-Up.
M. Thompson, et al.
PDF Poster

CONFERENCE POSTER
Treatment of HIV+ Subjects Co-infected with Hepatitis B or C: Week 60
Safety and Efficacy  Comparison of LPV/r vs. Nelfinavir from a Phase III
Blinded Randomized Clinical Trial.
B. Bernstein, et al.
PDF Poster